LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Diagnostic Testing Analyzed in Suspected Meningitis Diagnosis

By LabMedica International staff writers
Posted on 07 Dec 2021
Print article
Image: The FilmArray System Syndromic infectious disease testing impacts duration of empiric antibiotic therapy in suspected bacterial meningitis (Photo courtesy of BioFire Diagnostics)
Image: The FilmArray System Syndromic infectious disease testing impacts duration of empiric antibiotic therapy in suspected bacterial meningitis (Photo courtesy of BioFire Diagnostics)
Bacterial meningitis is a potentially fatal infection of the central nervous system (CNS) that is associated with significant complications including neurologic deficits and epilepsy in the majority of survivors.

Rapid diagnosis and treatment are critical to reducing morbidity and mortality; however, evaluation of suspected meningitis is complex and challenging due to its nonspecific presentation, the limited diagnostic utility of the clinical exam, and the requirement of cerebrospinal fluid (CSF) testing for diagnosis, which traditionally has long turnaround times for culture results and can be affected by antibiotic therapy initiated before performing lumbar puncture.

Medical Doctors at Weill Cornell Medicine (New York, NY, USA) performed a retrospective pre-post intervention study that included adults ≥18 years of age who presented to the emergency department with suspected bacterial meningitis defined by the following criteria: (1) received empiric antibiotic therapy for bacterial meningitis; (2) had lumbar puncture performed in the emergency department; and (3) underwent microbiological testing with CSF culture in the preintervention period and multiplex PCR ME panel testing plus CSF culture in the postintervention period.

The team analyzed the use of the FilmArray meningitis/encephalitis (ME) panel (BioFire Diagnostics, LLC, Salt Lake City, UT, USA), which has been US Food and Drug Administration-approved for use in community-acquired CNS infections, has permitted rapid identification (within 1 hour) of 14 different viral, bacterial, and fungal agents associated with ME in CSF using a multiplex polymerase chain reaction (PCR) system. The scientists gathered data from annual chart reviews over a 3-year period before and after implementation of the ME multiplex PCR panel on February 14, 2017. There were 137 patients in the pre-panel period and 69 patients in the post-panel period.

The investigators reported that the positive detection rate of bacterial pathogens was 3/137 (2.2%) by CSF culture in the pre-multiplex PCR ME panel period and 3/69 (4.3%) by the multiplex PCR ME panel in the post-multiplex PCR ME panel period. There was no difference in the proportion of patients for whom any pathogen was detected by microbiological testing between pre- and post-multiplex PCR ME panel periods (17.5% versus 20.3%). They found that once the panel was implemented, 46% more patients had empiric antibiotic therapy discontinued or de-escalated compared with before the panel was used.

Among 14 patients in the post-multiplex PCR ME panel period for whom a pathogen was identified, three patients had therapy targeted to bacterial pathogens (two S. pneumoniae, one H. influenzae) and 11 to viral pathogens (five enterovirus, three herpes simplex virus 2, three varicella zoster virus). The average turnaround time for the multiplex PCR ME panel was 2.6 hours. In the pre-multiplex PCR ME panel period, the average turnaround time for viral pathogen testing (performed by a viral encephalitis PCR panel on CSF samples) was 71.3 hours.

The authors concluded that implementation of a multiplex PCR ME panel for testing of adult patients who present to the emergency department with suspected bacterial meningitis appears to reduce the duration of empiric antibiotic therapy, time to targeted therapy, and possibly hospital length of stay compared with traditional microbiological testing methods. The study was published in the October, 2021 issue of the journal Open Forum Infectious Diseases.

Related Links:
Weill Cornell Medicine
BioFire Diagnostics


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.